{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:26:00Z","timestamp":1791487560673,"version":"4.3.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Myriad Genetics Inc"},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1093\/annonc\/mdy460","type":"journal-article","created":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T07:12:49Z","timestamp":1539587569000},"page":"2341-2347","source":"Crossref","is-referenced-by-count":244,"title":["Survival analysis of carboplatin added to an anthracycline\/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response\u2014final results from GeparSixto"],"prefix":"10.1016","volume":"29","author":[{"given":"S.","family":"Loibl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.E.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.M.","family":"Timms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.P.","family":"Elkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Hahnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.A.","family":"Fasching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Lederer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Denkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.T.","family":"Salat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rezai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.U.","family":"Blohmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.M.","family":"Zahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Jackisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Klare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"K\u00fcmmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Schem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Paepke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Schmutzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Rhiem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Penn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Nekljudova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-R.","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"von Minckwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Untch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdy460_bb0010","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(14)70160-3","article-title":"Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial","volume":"15","author":"von Minckwitz","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdy460_bb0015","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","article-title":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standardneoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial","volume":"19","author":"Loibl","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdy460_bb0020","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","volume":"33","author":"Sikov","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdy460_bb0025","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/jamaoncol.2017.1007","article-title":"Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the geparsixto randomized clinical trial","volume":"3","author":"Hahnen","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1093\/annonc\/mdy460_bb0030","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1200\/JCO.2011.38.2010","article-title":"Dissecting the heterogeneity of triple-negative breast cancer","volume":"30","author":"Metzger-Filho","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdy460_bb0035","first-page":"142","article-title":"DNA damage response pathways and cancer. Abeloff's Clinical Oncology","author":"Ford","year":"2014"},{"key":"10.1093\/annonc\/mdy460_bb0040","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2210-11-7","article-title":"Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells","volume":"11","author":"Alli","year":"2011","journal-title":"BMC Pharmacol"},{"key":"10.1093\/annonc\/mdy460_bb0045","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1093\/jnci\/djh312","article-title":"The role of BRCA1 in the cellular response to chemotherapy","volume":"96","author":"Kennedy","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdy460_bb0050","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1179\/1973947815Y.0000000061","article-title":"Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of rates of pathologic complete response and survival","volume":"28","author":"Kern","year":"2016","journal-title":"J Chemother"},{"key":"10.1093\/annonc\/mdy460_bb0055","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cncr.26351","article-title":"The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"118","author":"Kriege","year":"2012","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdy460_bb0060","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","article-title":"Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial","volume":"24","author":"Tutt","year":"2018","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdy460_bb0065","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1200\/JCO.2014.57.0085","article-title":"Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1\/2 mutation-associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105","volume":"33","author":"Telli","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdy460_bb0070","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1186\/s13058-014-0475-x","article-title":"Association of BRCA1\/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes","volume":"16","author":"Timms","year":"2014","journal-title":"Breast Cancer Res"},{"key":"10.1093\/annonc\/mdy460_bb0075","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdy460_bb0080","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1200\/JCO.2010.28.6450","volume":"29","author":"Valero","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdy460_bb0085","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1158\/1538-7445.SABCS15-S2-05","article-title":"Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +\/- carboplatin and\/or bevacizumab in triple-negative breast cancer: outcomes from CALGB 40603 (Alliance)","volume":"76","author":"Sikov","year":"2016","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdy460_bb0090","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ygyno.2017.08.022","article-title":"Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2","volume":"147","author":"Oza","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdy460_bb0095","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s10549-015-3435-y","article-title":"Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)","volume":"151","author":"Kaklamani","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdy460_bb0100","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1200\/JCO.2017.77.2285","article-title":"BRCA1\/2 Mutations and bevacizumab in the neoadjuvant treatment of breast cancer: response and prognosis results in patients with triple-negative breast cancer from the geparquinto study","volume":"36","author":"Fasching","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdy460_bb0105","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/annonc\/mdx821","article-title":"Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313)","volume":"29","author":"Sharma","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdy460_bb0110","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.519","article-title":"Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +\/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC","volume":"36","author":"Telli","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdy460_bb0115","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1200\/JCO.2014.57.6660","article-title":"TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer","volume":"33","author":"Isakoff","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419342462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419342462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/29\/12\/2341\/27342119\/mdy460.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T20:53:35Z","timestamp":1662238415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419342462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0923753419342462"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdy460","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}